Biotech

Cellular Biomedicine Group (NASDAQ:CBMG), a leading clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer, has announced its plan to configure part of its facility in Shanghai with GE Healthcare’s FlexFactory™ platform, which is expected to be designed to speed up manufacturing timelines for its cell therapy clinical trials and commercial launch. As …

Cellular Biomedicine Group (NASDAQ:CBMG), a leading clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer, has announced its plan to configure part of its facility in Shanghai with GE Healthcare’s FlexFactory™ platform, which is expected to be designed to speed up manufacturing timelines for its cell therapy clinical trials and commercial launch.
As quoted in the press release:

There are more than 900 regenerative medicine trials underway globally, including trials in cell and gene therapy, a 19 percent increase since 2016.1 Despite the increased number of precision medicine trials, gaps exist in how to manufacture these precise therapies to meet demand. Scalable integrated solutions to support the transition from clinical trials to commercialization have been limited.

Click here to read the full press release.

MARKETS

Markets
TSX19692.92+236.21
TSXV646.04+10.63
DOW32845.13+315.50
S&P 5004130.29+57.86
NASD12390.69+228.09
ASX6945.20+55.50

COMMODITIES

Commodities
Gold1766.26+0.25
Silver20.36+0.03
Copper3.59+0.12
Palladium2134.00+13.00
Platinum900.50+2.51
Oil98.30+1.88
Heating Oil3.53-0.08
Natural Gas8.29+0.15

DOWNLOAD FREE REPORTS

×